While subject matter expertise, relationships, and qualifications will always be critical for CRO selection, they are simple not sufficient criteria for sponsors who need to make a step change in efficiency.
Simply handing off multi-million-dollar studies to CROs without carefully crafted plans for communications and reporting operational data as the study unfolds is hardly a wise move, yet what kind of oversight is needed?
Reforecasting clinical trials based on the latest data and information can improve operations and overall trial performance and is a critical component of keeping your company’s plans in line with its financial position and on track to meet its goals.
The focus on technology as a driver of performance improvement in clinical trials is intense, but despite years of valiant efforts, study execution remains far from optimal. For study startup, the data are dismal.